glutathione and covid vaccine Frontiers Science & Tech Spotlight: COVID-19

2 World Journal of Gastroenterology (PMC)Sikiric P et al

The "minimal initial benefit" group (approximately 5-10% of users) reported limited improvements during treatment making discontinuation effects irrelevant, typically explained by inadequate product quality with degraded or low-concentration GHK-Cu, inappropriate application technique reducing absorption, unrealistic expectations exceeding what any topical can achieve, severe underlying pathology requiring medical intervention beyond cosmetic peptides, or individual non-responsiveness to copper peptide treatment for genetic or physiological reasons

Radiat Med Prot

Rustagi T, Jamidar PA